The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells

Camptothecin (CPT), a topoisomerase I-specific inhibitor, was found in this study to inhibit the replication of equine infectious anemia virus (EIAV) in chronically infected CF2Th cells (designated CF2Th/EIAV). By measuring viral reverse transcriptase activity in the culture medium, we demonstrated...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Virology 1991-08, Vol.65 (8), p.4137-4141
Main Authors: Priel, E. (Ben Gurion University of the Negev, Beer Sheva, Israel), Showalter, S.D, Roberts, M, Oroszlan, S, Blair, D.G
Format: Article
Language:English
Subjects:
Action of physical and chemical agents
Animals
Antigens, Viral - biosynthesis
Biological and medical sciences
Camptothecin - pharmacology
Cell Line
Cell Survival - drug effects
Fluorescent Antibody Technique
Fundamental and applied biological sciences. Psychology
Infectious Anemia Virus, Equine - drug effects
Infectious Anemia Virus, Equine - enzymology
Infectious Anemia Virus, Equine - immunology
Infectious Anemia Virus, Equine - physiology
INHIBICION
INHIBITION
LENTIVIRINAE
Microbiology
Radioimmunoprecipitation Assay
SUBSTANCE TOXIQUE
SUSTANCIAS TOXICAS
Topoisomerase I Inhibitors
Virology
Virus Replication - drug effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Camptothecin (CPT), a topoisomerase I-specific inhibitor, was found in this study to inhibit the replication of equine infectious anemia virus (EIAV) in chronically infected CF2Th cells (designated CF2Th/EIAV). By measuring viral reverse transcriptase activity in the culture medium, we demonstrated that treatment for 1 h with noncytotoxic doses of this drug inhibited production by 32 to 52%, whereas continuous exposure to this drug resulted in an 85 to 92% inhibition. No effect on the viability or growth rate of the cells was detected in any of these treatments. Indirect immunofluorescence analysis of the CPT-treated CF2Th/EIAV cells with anti-p26 capsid protein antibodies showed 60 to 85% reduction in the immunofluorescence-positive cells following drug treatment, and radioimmunoprecipitation analysis of these cells showed a comparable decrease of the pr55gag precursor protein. These data suggest that CPT acts as an anti-EIAV agent to block virus replication in the chronically infected cells
ISSN:0022-538X
1098-5514
DOI:10.1128/JVI.65.8.4137-4141.1991